Although historically breast cancer has been considered a non-immunogenic tumor (i.e. cold), TNBC appears more likely to respond to immunotherapy than other breast cancers because of an increased mutational burden, infiltration of the tumor microenvironment with immune cells (e.g., tumor-infiltrating lymphocytes), and higher expression of PD-L1 (14). The gene discussed is CD274; the disease is neoplasm.